Internship

Co-Op – Machine Learning

Spring 2025

Posted on 10/2/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Cambridge, MA, USA

Requires onsite presence in a hybrid capacity.

Category
Applied Machine Learning
Natural Language Processing (NLP)
AI & Machine Learning
Required Skills
Data Analysis
Requirements
  • A minimum of a BS in Physics, Mathematics, Computer Science, or a related technical field.
  • Currently enrolled in a graduate school program pursuing a Master’s or Ph.D. degree.
  • 1st author machine learning publication; Demonstrated ability to conduct independent machine learning research.
  • Candidate should have strong communication and presentation skills (written and verbal), and the ability to work in a collaborative environment.
Responsibilities
  • The candidate will gain practical knowledge of working with LLMs for proteins and geometric deep learning.
  • The candidate is expected to produce a technical report suitable for a machine learning conference workshop (such as NeurIPS) describing the impact of incorporating surface information into the LLMs.
  • Participate and contribute during scientific discussions.
  • Analyze data and present project findings at the conclusion of the program.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing access to effective and affordable healthcare solutions.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's involvement in Nobel Prize-winning immunology research underscores its leadership in groundbreaking scientific advancements.
  • The robust pipeline of molecular glues and other innovative therapies promises significant revenue growth and market expansion.
  • Recognition in the Dow Jones Sustainability Index North America highlights BMS's commitment to corporate responsibility and sustainability, enhancing its reputation and stakeholder trust.

What critics are saying

  • The termination of strategic collaborations, such as with Eisai, could impact BMS's ability to bring new therapies to market efficiently.
  • Ongoing layoffs and restructuring efforts may lead to decreased employee morale and potential disruptions in operations.

What makes Bristol-Myers Squibb unique

  • Bristol Myers Squibb's dual focus on innovative and generic medicines allows it to cater to a broad spectrum of healthcare needs, unlike competitors who may focus solely on one area.
  • Their commitment to sustainability and ESG goals sets them apart in the biopharmaceutical industry, appealing to socially conscious investors and stakeholders.
  • BMS's extensive R&D investment in oncology, immunology, and cardiovascular diseases positions it as a leader in developing cutting-edge treatments for serious diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE